TrialBreast cancer (Tokyo, Japan)2026

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.

Takashi Yamanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.